Improvements in survival among cancer patients have revealed the clinical impact of
cardiotoxicity on both cardiovascular and hematological and oncological outcomes …

Objective To undertake a systematic review and meta-analysis to assess the satisfaction of
patients receiving nonvitamin K anticoagulants (NOACs), compared with vitamin K …

Aims A Markov model was adapted to assess the real-world cost-effectiveness of
rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral …

Objective To evaluate the level of agreement between cardiologists regarding the
management of oral anticoagulation (OAC) in patients with non-valvular atrial fibrillation …

Background: The SAMe-TT2R2 score identifies patients on vitamin K antagonists (VKAs)
who are more likely to have poor time in therapeutic range (TTR); however, the association …

Background Worldwide, there is growing evidence that quality of international normalized
ratio (INR) control in atrial fibrillation patients treated with Vitamin K Antagonists (VKA) is …

Objective: To assess the major clinical factors affecting the quality of anticoagulation and
evaluate the predictive value of the SAMe-TT2R2 score to identify patients who will achieve …

Background Although, by itself, atrial fibrillation is associated with an impairment of quality of
life antithrombotic therapy may play a role. Objective To evaluate the satisfaction with …

Aim: To compare the satisfaction of patients treated with vitamin K antagonists (VKA) with
that of patients treated with direct oral anticoagulants (DOACs) and to determine the impact …

Introduction: The use of vitamin K antagonists (VKAs) in non-valvular atrial fibrillation (NVAF)
is complicated due to the narrow therapeutic margin they present and their unpredictable …